GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: hPT3 [3] | JNJ-3657 | JNJ-63733657 | JNJ3657 | JNJ63733657
Compound class:
Antibody
Comment: Posdinemab (JNJ-63733657) is a humanized IgG1/kappa monoclonal antibody that targets phosphorylated microtubule-associated protein tau. It binds to phosphorylated threonine residues in the protein's proline-rich domain. JNJ-63733657 was humanized from mouse parental antibody PT3 [3]. Phospho-tau reduction is proposed for the treatment of Alzheimer's disease.
|
| No information available. |
Summary of Clinical Use  |
| Posdinemab (JNJ-63733657) was progressed to clinical trials to determine safety and efficacy as a therapy for Alzheimer's disease [1,4]. Of note, UCB's anti-tau antibody bepranemab (which targets the same central domain as posdinemab) also failed to improve cognition and function in people with prodromal Alzheimer's [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03375697 | A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease | Phase 1 Interventional | Janssen Research & Development, LLC | 1 | |
| NCT05407818 | A Study of JNJ-63733657 in Healthy Chinese Participants | Phase 1 Interventional | Janssen Research & Development, LLC | 4 | |
| NCT04619420 | A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | Phase 2 Interventional | Janssen Research & Development, LLC | In November 2025 a statement from Johnson & Johnson revealed that posdinemab administration failed to significantly slow clinical decline in cognition and function in participants with early Alzheimer's disease, after a scheduled data review. As a result the study was stopped. | |
